Skip to main content

A real-world analysis finds no evidence of increased CV risk with tofacitinib vs. TNFi in RA

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
A real-world analysis finds no evidence of increased CV risk with tofacitinib vs. TNFi in RA

User login

Username

Password

Reset your password

Type	Lead	score